Nagao I, Nakazawa M, Tachibana Y, Kawasaki M, Ambrosini Y
Xenobiotica. 2024; 54(6):342-349.
PMID: 38819399
PMC: 11325560.
DOI: 10.1080/00498254.2024.2358395.
Chang C, Peng W, Lee W, Yang L, Lin T, Yang M
Commun Med (Lond). 2023; 3(1):150.
PMID: 37857815
PMC: 10587300.
DOI: 10.1038/s43856-023-00383-w.
Hau R, Wright S, Cherrington N
Clin Pharmacol Ther. 2023; 114(4):780-794.
PMID: 37404197
PMC: 11347013.
DOI: 10.1002/cpt.2984.
Nepal M, Taheri H, Li Y, Talebi Z, Uddin M, Jin Y
Cancer Res Commun. 2022; 2(11):1334-1343.
PMID: 36506732
PMC: 9730833.
DOI: 10.1158/2767-9764.crc-22-0172.
Li Y, Jin Y, Taheri H, Schmidt K, Gibson A, Buck S
Pharmaceutics. 2022; 14(9).
PMID: 36145680
PMC: 9502272.
DOI: 10.3390/pharmaceutics14091933.
The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes.
Kell D
Molecules. 2021; 26(18).
PMID: 34577099
PMC: 8470029.
DOI: 10.3390/molecules26185629.
Safety Evaluation of a New Traditional Chinese Medical Formula, Ciji-Hua'ai-Baosheng II Formula, in Adult Rodent Models.
Fu B, Zhai X, Xi S, Yue L, Wang Y, Qiu Y
Evid Based Complement Alternat Med. 2019; 2019:3659890.
PMID: 30733809
PMC: 6348800.
DOI: 10.1155/2019/3659890.
Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate).
Ceckova M, Reznicek J, Deutsch B, Fromm M, Staud F
PLoS One. 2018; 13(8):e0202706.
PMID: 30114293
PMC: 6095608.
DOI: 10.1371/journal.pone.0202706.
Influence of Orally Administered Borneol on the Expression of Hepatic Transporters in Rats.
Chen L, Liao L, Zhai T, Huang X, Chen Y
Eur J Drug Metab Pharmacokinet. 2018; 44(1):103-109.
PMID: 30105488
DOI: 10.1007/s13318-018-0499-1.
Pharmacogenetic Aspects of the Interaction of AT1 Receptor Antagonists With ATP-Binding Cassette Transporter .
Ripperger A, Krischer A, Robaa D, Sippl W, Benndorf R
Front Pharmacol. 2018; 9:463.
PMID: 29867471
PMC: 5960723.
DOI: 10.3389/fphar.2018.00463.
Nanoparticles and Controlled Delivery for Bioactive Compounds: Outlining Challenges for New "Smart-Foods" for Health.
Martinez-Ballesta M, Gil-Izquierdo A, Garcia-Viguera C, Dominguez-Perles R
Foods. 2018; 7(5).
PMID: 29735897
PMC: 5977092.
DOI: 10.3390/foods7050072.
Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
Stopfer P, Giessmann T, Hohl K, Hutzel S, Schmidt S, Gansser D
Br J Clin Pharmacol. 2018; 84(9):1941-1949.
PMID: 29665130
PMC: 6089804.
DOI: 10.1111/bcp.13609.
Transporter-Guided Delivery of Nanoparticles to Improve Drug Permeation across Cellular Barriers and Drug Exposure to Selective Cell Types.
Kou L, Bhutia Y, Yao Q, He Z, Sun J, Ganapathy V
Front Pharmacol. 2018; 9:27.
PMID: 29434548
PMC: 5791163.
DOI: 10.3389/fphar.2018.00027.
Assessment of the Drug Interaction Potential of Unconjugated and GalNAc-Conjugated 2'-MOE-ASOs.
Shemesh C, Yu R, Warren M, Liu M, Jahic M, Nichols B
Mol Ther Nucleic Acids. 2017; 9:34-47.
PMID: 29246313
PMC: 5602538.
DOI: 10.1016/j.omtn.2017.08.012.
Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail.
Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub M
Eur J Drug Metab Pharmacokinet. 2017; 43(1):69-80.
PMID: 28685495
PMC: 5794840.
DOI: 10.1007/s13318-017-0427-9.
Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype.
Fattah S, Shinde A, Matic M, Baes M, van Schaik R, Allegaert K
Pharm Res. 2017; 34(6):1309-1319.
PMID: 28364304
DOI: 10.1007/s11095-017-2148-9.
Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub M
Clin Pharmacol Ther. 2016; 100(3):259-67.
PMID: 27256812
PMC: 5102573.
DOI: 10.1002/cpt.406.
Impact of New Genomic Technologies on Understanding Adverse Drug Reactions.
Maggo S, Savage R, Kennedy M
Clin Pharmacokinet. 2015; 55(4):419-36.
PMID: 26369774
PMC: 4791456.
DOI: 10.1007/s40262-015-0324-9.
Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.
Pabla N, Gibson A, Buege M, Ong S, Li L, Hu S
Proc Natl Acad Sci U S A. 2015; 112(16):5231-6.
PMID: 25848011
PMC: 4413320.
DOI: 10.1073/pnas.1424313112.
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion.
Kell D, Oliver S
Front Pharmacol. 2014; 5:231.
PMID: 25400580
PMC: 4215795.
DOI: 10.3389/fphar.2014.00231.